Houcai Wang

301 Yanchang Road
Shanghai, 200072, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

CAPN1 is a novel biomaker of patients with AML based on comprehensive analysis.

CAPN1 is a novel biomaker of patients with AML based on comprehensive analysis.

Journal: Biotechnology & genetic engineering reviews

Published: April 28, 2023

Quercetin inhibits the proliferation of multiple myeloma cells by upregulating PTPRR expression.

Quercetin inhibits the proliferation of multiple myeloma cells by upregulating PTPRR expression.

Journal: Acta biochimica et biophysica Sinica

Published: April 10, 2021

A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway.

A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway.

Journal: Cancer cell international

Published: March 02, 2021

A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling.

A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling.

Journal: American journal of translational research

Published: April 24, 2020

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 30, 2019

Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.

Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.

Journal: International journal of oncology

Published: January 24, 2018

DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma.

DCZ3301, a novel aryl-guanidino inhibitor, induces cell apoptosis and cell cycle arrest via suppressing the PI3K/AKT pathway in T-cell leukemia/lymphoma.

Journal: Acta biochimica et biophysica Sinica

Published: December 17, 2017

DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.

DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.

Journal: Cell death & disease

Published: June 08, 2017

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.

Journal: Theranostics

Published: November 14, 2016

TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.

TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.

Journal: Oncotarget

Published: April 16, 2016

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.

Journal: Oncotarget

Published: December 02, 2015

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.

Journal: Oncotarget

Published: November 11, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026